Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27864671 | 0.89 | TAAR1 (0.59) | ACHEALOX15MAOAMAOBTAAR1 | |
| SCHEMBL28554715 | 0.88 | ALOX15 (0.54) | ACHEALOX15MAOAMAOBTAAR1 | |
| SCHEMBL1787452 | 0.84 | CYP3A4 (0.54) | ACHEMAOAMAOBTAAR1KMT2A | |
| SCHEMBL26153362 | 0.83 | ACHE (0.61) | ACHEESR1HIF1AELANEKMT2A | |
| SCHEMBL6670104 | 0.82 | ACHE (0.59) | ACHEESR1HIF1AELANEKMT2A | |
| SCHEMBL10782553 | 0.81 | ACHE (0.71) | ACHEESR1HIF1AELANEKMT2A | |
| SCHEMBL28593564 | 0.81 | ACHE (0.58) | ACHEESR1HIF1AELANEKMT2A | |
| SCHEMBL29542913 | 0.81 | ACHE (0.58) | ACHEESR1HIF1AELANEKMT2A | |
| SCHEMBL27543028 | 0.81 | ACHE (0.58) | ACHEMAOBESR1HIF1AELANE | |
| SCHEMBL5258931 | 0.81 | ACHE (0.58) | ACHEESR1HIF1AELANEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134362-B1 | IBUPROFEN ESTER DERIVATIVE AND EMULSION FORMULATION THEREOF | NANJING HERON PHARMACEUTICAL SCIENCE AND TECH CO LTD (CN) | 2024-02-28 | — | — | EP | claimed |
| US-20230126556-A1 | IBUPROFEN ESTER DERIVATIVE AND EMULSION PREPARATION THEREOF | NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-04-27 | — | — | US | claimed |
| EP-4134362-A1 | IBUPROFEN ESTER DERIVATIVE AND EMULSION FORMULATION THEREOF | Nanjing Heron Pharmaceutical Science and Technology Co., Ltd. (CN) | 2023-02-15 | — | — | EP | claimed |
| CN-114728883-A | Ibuprofen ester prodrug, pharmaceutical composition, preparation method and application | 南京海融医药科技股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114728882-A | Ibuprofen ester derivative and emulsion preparation thereof | 南京海融医药科技股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114380785-A | Ibuprofen derivative, preparation method and application | 南京海融医药科技股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| US-9089549-B2 | Compositions and methods for preventing cardiac arrhythmia | CORMATRIX CARDIOVASCULAR, INC. (US) | 2015-07-28 | — | — | US | claimed |
| US-20150150914-A1 | Compositions and Methods for Preventing Cardiac Arrhythmia | CORVIVO CARDIOVASCULAR, INC. | 2015-06-04 | — | — | US | claimed |
| CN-104529959-A | Synthesis method of ramelteon | JIANGSU JIAYI PHARMACEUTICAL CO LTD | 2015-04-22 | — | — | CN | claimed |
| US-20070020245-A1 | Composition for the treatment of arthrosis/arthritis, especially for treating joints | TROTT KATHARINA | 2007-01-25 | — | — | US | claimed |
| JP-9002949-A | — | — | None | — | — | JP | disclosed |
| US-20250177307-A1 | IMPROVED MANUFACTURING PROCESS | HALEON (SUZHOU) PHARMACEUTICAL CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| CN-114728883-B | Ibuprofen ester prodrug, pharmaceutical composition, preparation method and application | 南京海融医药科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117355527-B | Anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118020932-A | Application of Meinaria fruit leaf extract in reducing arecoline toxicity | 华南农业大学 | 2024-05-14 | — | — | CN | disclosed |
| US-5266723-A | Process for the preparation of optically active 2-aryl-alkanoic acids, especially 2-aryl-propionic acids | MEDICE, LTD., CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) | 1993-11-30 | — | — | US | disclosed |
| US-5248815-A | STEREO-SELECTIVE SYNTHESIS OF 2-ARYL-PROPIONIC ACIDS OF HIGH OPTICAL PURITY BY USING CHIRAL OXAZOLINES | PARADIES HENRICH H (DE) | 1993-09-28 | — | — | US | disclosed |
| WO-1993013046-A1 | STEREO-SELECTIVE SYNTHESIS OF 2-ARYL-PROPIONIC ACIDS OF HIGH OPTICAL PURITY BY USING CHIRAL OXAZOLINES | KUNICHEM, INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| EP-0110671-B1 | PREPARATION OF OPTICALLY ACTIVE ALPHA-ARYLALKANOIC ACIDS AND PRECURSORS THEREOF | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1986-05-21 | — | — | EP | disclosed |
| JP-H00710749-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126556-A1 | IBUPROFEN ESTER DERIVATIVE AND EMULSION PREPARATION THEREOF | CYP2C9, CYP2C19, CYP4B1 | ACHE 648/4885ALOX15 98/4885MAOA 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.